Our Pipeline
Discovery Programs
The Company currently has active programs in three target areas: (a) the development of new drugs (b) agricultural chemicals (herbicides and insecticides) (c) industrial chemicals.
Patents
IP estate with 5 issued and 2 pending patent applications.
Publications
Scientific peer-reviewed publications.
Pipeline
R&D pipeline covering all major disease areas.
Therapeutics
M-Life™ leverages botanicals for the design of new molecules. In total, 11 therapeutic programs comprise the Company’s current pipeline.
Other Programs
The Company’s pipeline includes molecules for non-therapeutic applications. These include fluorescent molecules (fluorophores) for use in a number of applications including OLED TV’s, Lasers and reagent labeling. As well, the M-Life™ herbicide and insecticide programs address a market need for new non-toxic weed and pest control.
Cancer Therapeutics, A New Take on Tubulin Inhibitors
The Company’s current efforts center on the design of both new multi-targeting-agents (MTA’s), or chimeras, as well as the advancement of M-Life™ licensed tubulin targeting molecules for use in the treatment of pediatric Acute Myeloid Leukemia (AML). M-Life™ programs leverage the published works of Dr. Peter Crooks, M-Life™ Chief Discovery Officer and M-Life™’s proprietary design platforms. The initial commercialization strategy is to advance the licensed tubulin molecules novel chimera molecules through IND. Once significant advancement of these molecules is made through the FDA approval process, therapeutic applicability will be expanded to include CNS and many other types of cancer.
The M-Life™ Molecule Intellectual Property Portfolio
- Provisional Patent Applications 62/927,744 and 62/947,031
- US Pat. No. 9,597,316, US Pat. No. 9,884,842, US Pat. No. 10,100,029, US Pat. No. 9,938,246
and US Pat. No. 10,239,844 - Various In-work Provisional Patent Applications for molecules in multiple therapeutic classes
